Abstract:Pancreatic ductal adenocarcinoma (PDAC), a leading cause of cancer mortality in the United States, presents significant treatment challenges due to its late diagnosis and poor prognosis. Despite advances, the five-year survival rates remain dismally low, with only a fraction of patients eligible for potentially curative surgical interventions. This review aims to comprehensively examine the current landscape of targeted therapies in PDAC, focusing on recent developments in precision medicine approaches. We explore various molecular targets, including KRAS mutations, DNA damage repair deficiencies, mismatch repair pathway alterations, and rare genetic fusions. The review discusses emerging therapies, such as PARP inhibitors, immune checkpoint inhibitors, and novel targeted agents, like RET and NTRK inhibitors. We analyze the results of key clinical trials and highlight the potential of these targeted approaches in specific patient subgroups. Recent developments in PDAC research have emphasized precision oncology, facilitated by next-generation sequencing and the identification of genetic and epigenetic alterations. This approach tailors treatments to individual genetic profiles, improving outcomes and reducing side effects. Significant strides have been made in classifying PDAC into various subtypes, enhancing therapeutic precision. The identification of specific mutations in genes like KRAS, along with advancements in targeted therapies, including small molecule inhibitors, offers new hope. Furthermore, emerging therapies targeting DNA repair pathways and immunotherapeutic strategies also show promising results. As research evolves, integrating these targeted therapies with conventional treatments might improve survival rates and quality of life for PDAC patients, underscoring the shift towards a more personalized treatment paradigm.

Advances in Systemic Therapy in Pancreatic Cancer

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

Pancreatic cancer: new approaches to drug therapy

Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions

Advancing Immunotherapy in Pancreatic Cancer

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine

Updates in Immunotherapy for Pancreatic Cancer

Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review

The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects

Pancreatic Ductal Adenocarcinoma: Current and Emerging Treatments

Recent Advances in the Treatment of Pancreatic Cancer

Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer

Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation

Consensus, debate, and prospective on pancreatic cancer treatments

Pancreatic cancer treatment: better, but a long way to go

Novel Agents for Pancreatic Ductal Adenocarcinoma: Emerging Therapeutics and Future Directions

[Advances in Immunotherapy of Pancreatic Ductal Adenocarcinoma].

[Molecular Targeted Therapy Strategy and Clinical Research Progress in Pancreatic Ductal Adenocarcinoma].